Cost-effectiveness analysis of neoadjuvant versus adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer patients during initial treatment phase.

ABSTRACT:

Objective

The choice between neoadjuvant chemotherapy (NAC) and adjuvant chemotherapy (AC) remains controversial in the treatment of non-small cell lung cancer (NSCLC). There is no significant difference in NAC and AC's effectiveness. We investigate the cost-effectiveness of NAC versus AC for NSCLC.

Method

A decision tree model was designed from a payer perspective to compare NAC and AC treatments for NSCLC patients. Parameters included overall survival (OS), surgical complications, chemotherapy adverse events (AEs), treatment initiation probability, treatment time frame, treatment cost, and quality of life (QOL). Sensitivity analyses were performed to characterize model uncertainty in the base cases.

Result

AC treatment strategy produced a cost saving of ¥3064.90 and

SUBMITTER: Wu D 

PROVIDER: S-EPMC8287679 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature